Improved detection of prostate cancer using classification and regression tree analysis.

PURPOSE To build a decision tree for patients suspected of having prostate cancer using classification and regression tree (CART) analysis. PATIENTS AND METHODS Data were uniformly collected on 1,433 referred men with a serum prostate-specific antigen (PSA) levels of < or = 10 ng/mL who underwent a prostate biopsy. Factors analyzed included demographic, laboratory, and ultrasound data (ie, hypoechoic lesions and PSA density [PSAD]). Twenty percent of the data was randomly selected and reserved for study validation. CART analysis was performed in two steps, initially using PSA and digital rectal examination (DRE) alone and subsequently using the remaining variables. RESULTS CART analysis selected a PSA cutoff of more than 1.55 ng/mL for further work-up, regardless of DRE findings. CART then selected the following subgroups at risk for a positive biopsy: (1) PSAD more than 0.165 ng/mL/cc; (2) PSAD < or = 0.165 ng/mL/cc and a hypoechoic lesion; (3) PSAD < or = 0.165 ng/mL/cc, no hypoechoic lesions, age older than 55.5 years, and prostate volume < or = 44.0 cc; and (4) PSAD < or = 0.165 ng/mL/cc, no hypoechoic lesions, age older than 55.5 years, and 50.25 cc less than prostate volume < or = 80.8 cc. In the validation data set, specificity and sensitivity were 31.3% and 96.6%, respectively. Cancers that were missed by the CART were Gleason score 6 or less in 93.4% of cases. Receiver operator characteristic curve analysis showed that CART and logistic regression models had similar accuracy (area under the curve = 0.74 v 0.72, respectively). CONCLUSION Application of CART analysis to the prostate biopsy decision results in a significant reduction in unnecessary biopsies while retaining a high degree of sensitivity when compared with the standard of performing a biopsy of all patients with an abnormal PSA or DRE.

[1]  R. Babaian,et al.  Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer. , 1999, Seminars in oncology.

[2]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[3]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[4]  T. H. van der Kwast,et al.  Serendipity in detecting disease in low prostate‐specific antigen ranges , 2002, BJU international.

[5]  J Murtaugh,et al.  Early detection. , 1999, Journal of the American Dental Association.

[6]  Louis R Kavoussi,et al.  Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. , 1994, The Journal of urology.

[7]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[8]  William J Catalona,et al.  Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.

[9]  Harry J de Koning,et al.  Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial , 2002, International journal of cancer.

[10]  H. D. de Koning,et al.  Prostate cancer detection at low prostate specific antigen. , 2000, The Journal of urology.

[11]  P. McCullagh,et al.  Generalized Linear Models , 1992 .

[12]  A. Partin,et al.  An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. , 1998, Urology.

[13]  M. Kattan,et al.  Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. , 1999, Urology.

[14]  J. Hugosson,et al.  Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region) , 1999, The Prostate.

[15]  D L McCullough,et al.  Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. , 1997, The Journal of urology.

[16]  J. Richie,et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. , 2000, Urology.

[17]  Risks and Complications of Transrectal Ultrasound Guided Prostate Needle Biopsy: A Prospective Study and Review of the Literature , 1999 .

[18]  Yi-Ching Hsieh,et al.  Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL , 2003, Cancer.

[19]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[20]  Louis R Kavoussi,et al.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. , 1994, The Journal of urology.

[21]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[22]  H. Carter,et al.  Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. , 1997, The Urologic clinics of North America.

[23]  G. Murphy,et al.  Prostatic evaluation by transrectal sonography: criteria for diagnosis of early carcinoma. , 1986, Radiology.

[24]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.

[25]  Fritz H. Schröder,et al.  Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer , 1998 .

[26]  W. Ellis,et al.  Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. , 1994, The Journal of urology.

[27]  W. Catalona,et al.  Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. , 1999, The Journal of urology.

[28]  D. Ornstein,et al.  A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. , 2000, The Journal of urology.

[29]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[30]  P. J. van der Maas,et al.  Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. , 1999, Journal of the National Cancer Institute.

[31]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[32]  G. Bartsch,et al.  Early detection of prostate cancer with low PSA cut‐off values leads to significant stage migration in radical prostatectomy specimens , 2003, The Prostate.

[33]  D. Chan,et al.  Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. , 1997, JAMA.

[34]  J. Oesterling,et al.  Interpreting results of prostate-specific antigen testing for early detection of prostate cancer , 1996, Journal of General Internal Medicine.

[35]  Mesut Remzi,et al.  Novel artificial neural network for early detection of prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Scardino,et al.  The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. , 1989, The Journal of urology.